$82.00
-1.80[-2.15%]
At close: May 3
$82.00
0[0.00%]
After Hours: 5:16PM EDT
Biomarin Pharmaceutical
(NASDAQ:BMRN)Biomarin Pharmaceutical Stock (NASDAQ:BMRN), Guidance and Forecast
Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period.
Date Announced | ticker | Company Name | Period | Period Year | Min EPS | Max EPS | Estimate | Min Rev | Max Rev | Revenue Estimate | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/24/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $2.75 | $2.95 | $1.65 | $2.70B | $2.80B | $2.77B | Get Alert |
| 02/22/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $2.60 | $2.80 | $1.96 | $2.70B | $2.80B | $2.83B | Get Alert |
| 11/01/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.90 | $2.05 | $1.02 | $2.39B | $2.47B | $2.45B | Get Alert |
| 07/31/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.85 | $2.10 | $1.02 | $2.38B | $2.50B | $2.46B | Get Alert |
| 04/26/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.80 | $2.05 | $0.95 | $2.38B | $2.50B | $2.46B | Get Alert |
| 02/27/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.80 | $2.05 | $1.61 | $2.38B | $2.50B | $2.58B | Get Alert |
| 10/26/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.06B | $2.16B | $2.12B | Get Alert |
| 08/03/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.06B | $2.16B | $2.11B | Get Alert |
| 04/27/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.05B | $2.15B | $2.10B | Get Alert |
| 02/23/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.05B | $2.15B | $2.14B | Get Alert |
| 10/27/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.82B | $1.88B | $1.85B | Get Alert |
| 07/28/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.79B | $1.88B | $1.82B | Get Alert |
| 04/29/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.75B | $1.85B | $1.81B | Get Alert |
| 02/25/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.75B | $1.85B | $1.91B | Get Alert |
| 11/05/2020 | BMRN | Biomarin Pharmaceutical | FY | 2020 | — | — | — | $1.81B | $1.87B | $1.86B | Get Alert |
| 08/04/2020 | BMRN | Biomarin Pharmaceutical | FY | 2020 | — | — | — | $1.85B | $1.95B | $1.90B | Get Alert |
| 04/29/2020 | BMRN | Biomarin Pharmaceutical | FY | 2020 | — | — | — | $1.85B | $1.95B | $1.97B | Get Alert |
| 02/26/2020 | BMRN | Biomarin Pharmaceutical | FY | 2020 | — | — | — | $1.95B | $2.05B | $1.95B | Get Alert |
| 10/23/2019 | BMRN | Biomarin Pharmaceutical | FY | 2019 | — | — | — | $1.69B | $1.72B | $1.70B | Get Alert |
FAQ
What is the most recent guidance for Biomarin Pharmaceutical (BMRN)?
The last reported Earnings numbers were from April 24, 2024 for the full year 2024 and was for an earnings per share guidance in the range of $2.75 and $2.95 versus the estimated EPS of $1.65.
Browse guidance and forecast on all stocks.